Evenity (romosozumab) is an antibody pharmaceutical. Romosozumab was first approved as Evenity on 2019-04-09. It is used to treat postmenopausal osteoporosis in the USA. It has been approved in Europe to treat osteoporosis. The pharmaceutical is active against sclerostin.
|Indication||osteoporosis, postmenopausal osteoporosis|
|Drug Class||Monoclonal antibodies: humanized, bone target|